TG THERAPEUTICS, INC.

Listed Company

TGTXCIK 0001001316NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$616.29M

Net Income

$447.18M

Total Assets

$1.06B

Equity

$648.02M

Shares Out

153.08M

Op. Cash Flow

$-24.77M

TGTX$54.87+39.94% · past yearDBEQ Basic

Daily closing prices

Business

TG Therapeutics is a commercial-stage biotechnology company focused on acquiring, developing and commercializing novel treatments for B-cell mediated diseases. The company's lead product, BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody, is FDA-approved for relapsing forms of multiple sclerosis and commercially launched in the U.S. and European markets. The pipeline includes subcutaneous ublituximab and azer-cel, an allogeneic CAR T cell therapy for autoimmune diseases, both in clinical development. TG distributes BRIUMVI directly in the U.S. and through exclusive commercialization partnerships internationally, particularly with Neuraxpharm for ex-U.S. markets.

Summary from 10-K filed 2026-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	616	329	234	3	7
Cost of revenue	101	38	14	265,000	790,000
Noncash compensation	17	11	13	13	24
Other research and development	144	83	63	112	199
Total research and development	160	94	76	125	223
Noncash compensation	48	31	25	31	37
Other selling, general and administrative	184	123	98	64	91
Total selling, general and administrative	232	154	123	95	128
Total costs and expenses	493	287	213	221	351
Operating income	123	42	21	−218	−345
Interest expense	27	24	13	10	—
Other income	−11	−8	−5	−5	−2
Total other expense	16	16	8	5	3
Net income before taxes	107	26	13	−224	−348
Income tax benefit (expense)	340	−2	−390,000	0	0
Net income	447	23	13	−224	−348
Basic (in dollars per share)	3.1	0.16	0.09	−1.65	−2.63
Diluted (in dollars per share)	2.77	0.15	0.09	−1.65	−2.63
Basic (in shares)	144	145	142	135	132
Diluted (in shares)	161	160	149	135	132

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	79	180	93	102	299
Short-term investment securities	63	131	125	59	16
Accounts receivable, net	306	129	51	0	—
Inventory	126	110	40	0	—
Other current assets	58	16	10	2	3
Total current assets	631	566	318	168	331
Restricted cash	1	1	1	1	1
Long-term investment securities	59	808,000	0	12	36
Right of use assets	6	7	8	9	9
Deferred tax assets	348	0	—	—	—
Long-term Inventory	16	0	—	—	—
Other noncurrent assets	2	2	2	—	—
Total assets	1,063	578	330	194	380
Accounts payable and accrued expenses	108	58	38	42	51
Other current liabilities	2	5	1	1	2
Lease liability current portion	1	1	1	2	1
Deferred revenue - current portion	21	11	152,000	—	—
Accrued compensation	22	15	12	8	10
Total current liabilities	154	91	54	53	65
Deferred revenue, non-current portion	9	12	6	305,000	457,000
Loan payable non-current	246	244	100	71	67
Lease liability non-current	7	8	9	10	10
Total liabilities	415	355	169	135	142
Commitments and contingencies	—	—	—	—	—
Common stock, $0.001 par value per share (190,000,000 and 190,000,000 shares authorized, 158,849,596 and 156,204,159 shares issued, 155,305,953 and 155,836,256 shares outstanding at December 31, 2025 and December 31, 2024, respectively)	159,000	156,000	151,000	146,000	143,000
Additional paid-in capital	1,830	1,760	1,713	1,586	1,566
Treasury stock, at cost, 3,543,643 and 367,903 shares at December 31, 2025 and December 31, 2024	−100	−9	—	—	−200,000
Accumulated deficit	−1,100	−1,529	−1,553	−1,500	−1,329
Total stockholders equity	648	222	161	59	237
Total liabilities and stockholders equity	1,063	578	330	194	380

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Loss on extinguishment of debt	0	5	0	0	—
Noncash stock compensation expense	65	43	38	45	61
Depreciation and amortization	59,000	68,000	211,000	303,000	282,000
Amortization of discount on investment securities	−4	−7	−2	−331,000	517,000
Amortization of debt issuance costs	1	2	2	2	1
Amortization of leasehold interest	185,000	212,000	212,000	212,000	212,000
Deferred income taxes	348	0	0	—	—
Noncash change in lease liability and right of use asset	2	2	2	3	2
Change in fair value of equity investments	298,000	754,000	0	0	—
Change in fair value of notes payable	27,000	304,000	113,000	−116,000	−578,000
Change in inventory reserve	6	0	0	—	—
Increase in inventory	−33	−67	−37	0	0
Increase in other current assets	−42	−6	−3	8	−9
Increase in accounts receivable	−176	−78	−51	1	−1
Increase in accounts payable and accrued expenses	56	23	192,000	−11	16
Decrease in lease liabilities	−2	−2	−2	−2	−2
(Decrease) increase in other current liabilities	−2	4	3	2	−16
Increase in deferred revenue	6	17	6	−152,000	−152,000
Net cash used in operating activities	−25	−41	−31	−176	−296
Proceeds from maturity of held-to-maturity securities	238	311	96	—	—
Investment in held-to-maturity securities	−222	−311	−147	−107	−56
Investment in equity investments	−1	−1	0	—	—
Purchases of Property, Plant and Equipment	−214,000	−45,000	0	−14,000	−401,000
Net cash provided by (used in) investing activities	14	−1	−51	−20	−332,000
Payment of loan payable	0	−108	0	−975,000	−30
Issuance of common stock, net	0	0	46	0	2
Proceeds from exercise of options	2	914,000	2	584,000	216,000
Proceeds from debt financings	0	245	25	0	70
Financing costs paid	0	−889,000	−125,000	0	−1
Purchase of treasury stock	−91	−9	0	0	—
Net cash (used in) provided by financing activities	−90	129	73	−391,000	41
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	−101	87	−9	−197	−255
Interest	24	18	9	5	3
Income taxes	8	500,000	0	0	—
Deferred Financing Costs	0	0	1	0	0
Warrants issued with debt financing	0	0	595,000	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is TG THERAPEUTICS, INC.'s CIK number?

TG THERAPEUTICS, INC.'s SEC CIK number is 0001001316 (1001316). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find TG THERAPEUTICS, INC.'s SEC filings?

All of TG THERAPEUTICS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did TG THERAPEUTICS, INC. last report earnings?

TG THERAPEUTICS, INC. (TGTX) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-015013). This is TG THERAPEUTICS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is TG THERAPEUTICS, INC.'s most recent earnings 8-K?

TG THERAPEUTICS, INC.'s latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001437749-26-015013. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View TG THERAPEUTICS, INC.'s latest earnings 8-K →
Look up any company's CIK number →